Jan 25, 2024 · TARRYTOWN, N.Y. and PARIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug …

Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb …

Jun 27, 2024 · Dupilumab resulted in histologic remission in a significantly higher percentage of children with eosinophilic esophagitis than placebo. The higher-exposure dupilumab regimen also led to …

Sep 11, 2025 · Dupixent for EOE Side Effects While Dupixent for eosinophilic esophagitis is generally well tolerated, side effects most often include injection-site reactions, upper respiratory infections, …

The Disease Eosinophilic esophagitis (EoE) is a long-term, inflammatory disease of the esophagus, affecting children and adults In children, it causes symptoms such as vomiting, pain, and difficulty …

Jan 25, 2019 · Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a …

Dec 21, 2022 · Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. We conducted a three-part, phase 3 trial …

Feb 21, 2024 · The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed the safety and …

Dec 11, 2024 · Long-term management options for EoE have remained a significant unmet need in the field. This study bridges that gap by demonstrating that weekly 300 mg dupilumab is well tolerated …

Dec 22, 2022 · Among patients with eosinophilic esophagitis, subcutaneous dupilumab administered weekly improved histologic outcomes and alleviated symptoms of the disease. (Funded by Sanofi …